Page 80 - 《中国药房》2025年18期

Thailand[J]. Diabetes Ther，2021，12（7）：1947-1963. tients with type 2 diabetes in China[J]. Front Pharmacol，
[16] MOSENZON O，WIVIOTT S D，HEERSPINK H J L，et 2019，10：480.
al. The effect of dapagliflozin on albuminuria in [26] HONG Z，ZHUANG Y，LU J，et al. Economic evaluation
DECLARE-TIMI 58[J]. Diabetes Care，2021，44（8）： of three dialysis methods in patients with end-stage renal
1805-1815. disease in China[J]. Int Urol Nephrol，2023，55（5）：1247-
[17] MAYER G J，WANNER C，WEIR M R，et al. Analysis 1254.
from the EMPA-REG OUTCOME trial indicates empa‐ [27] LI C Y，ZHOU H J，WANG P. Health utility of type 2 dia‐
®
gliflozin may assist in preventing the progression of betes patients using basal insulin in China：results from
chronic kidney disease in patients with type 2 diabetes ir‐ the BEYOND Ⅱ study[J]. Acta Diabetol，2021，58（3）：
respective of medications that alter intrarenal hemodyna- 329-339.
mics[J]. Kidney Int，2019，96（2）：489-504. [28] ZHANG Y，LI J Y，YANG L. Health-related quality of
[18] GAO B X，WU S L，WANG J W，et al. Clinical features life of Chinese patients with chronic kidney disease：a
and long-term outcomes of diabetic kidney disease： a pro- study based on four EQ-5D-3L value sets[J]. Sci Rep，
spective cohort study from China[J]. J Diabetes Complica‐ 2023，13（1）：7863.
tions，2019，33（1）：39-45. [29] GU S Y，SHI L Z，SHAO H，et al. Choice across 10 phar‐
[19] WU B，ZHANG S H，LIN H W，et al. Prevention of renal macologic combination strategies for type 2 diabetes：a
failure in Chinese patients with newly diagnosed type 2 cost-effectiveness analysis[J]. BMC Med，2020，18
diabetes：a cost-effectiveness analysis[J]. J Diabetes Inves‐ （1）：378.
tig，2018，9（1）：152-161. [30] Kidney Disease：Improving Global Outcomes（KDIGO）
[20] YANG F，LIAO M X，WANG P S，et al. Cost- CKD Work Group. KDIGO 2024 clinical practice guide‐
effectiveness analysis of renal replacement therapy strate‐ line for the evaluation and management of chronic kidney
gies in Guangzhou city，Southern China[J]. BMJ Open， disease[J]. Kidney Int，2024，105（Suppl. 4）：S117-S314.
2021，11（2）：e039653. [31] JUNG C Y，YOO T H. Pathophysiologic mechanisms and
[21] TONG P Y，KONG A P，SO W Y，et al. Interactive effect potential biomarkers in diabetic kidney disease[J]. Diabe‐
of retinopathy and macroalbuminuria on all-cause morta- tes Metab J，2022，46（2）：181-197.
lity，cardiovascular and renal end points in Chinese pa‐ [32] KLUGER A Y，TECSON K M，BARBIN C M，et al. Car‐
tients with type 2 diabetes mellitus[J]. Diabet Med，2007， diorenal outcomes in the CANVAS，DECLARE-TIMI 58，
24（7）：741-746. and EMPA-REG OUTCOME trials：a systematic review
[22] HUANG K Y，WANG Y，SUN S J，et al. Cost- [J]. Rev Cardiovasc Med，2018，19（2）：41-49.
effectiveness analysis of dapagliflozin plus standard treat‐ [33] SHIAU C H，TSAU L Y，KAO C C，et al. Efficacy and
ment for patients with type 2 diabetes and high risk of car‐ safety of sodium-glucose cotransporter-2 inhibitors in pa‐
diovascular disease in China[J]. Front Public Health， tients with chronic kidney disease：a systematic review
2022，10：936703. and meta-analysis[J]. Int Urol Nephrol，2024，56（4）：
[23] 中华医学会糖尿病学分会，国家基本公共卫生服务项目 1359-1381.
基层糖尿病防治管理办公室. 国家基层糖尿病肾脏病防 [34] GOURZOULIDIS G，TZANETAKOS C，IOANNIDIS I，
治技术指南：2023[J]. 中华内科杂志，2023，62（12）： et al. Cost-effectiveness of empagliflozin compared with
1394-1405. dapagliflozin for the treatment of patients with type 2 dia‐
[24] WEI R，WANG W H，HUANG X S，et al. Evaluating the betes mellitus and established cardiovascular disease in
long-term cost-effectiveness of fixed-ratio combination in‐ Greece[J]. Clin Drug Investig，2021，41（4）：371-380.
sulin degludec/liraglutide（IDegLira）versus other treat‐ [35] NEAL B，PERKOVIC V，MAHAFFEY K W，et al. Cana‐
ment regimens in the Chinese type 2 diabetes patients[J]. gliflozin and cardiovascular and renal events in type 2 dia‐
Diabetol Metab Syndr，2023，15（1）：173. betes[J]. N Engl J Med，2017，377（7）：644-657.
[25] HOU X Y，WAN X，WU B. Cost-effectiveness of cana‐ （收稿日期：2024-10-16 修回日期：2025-08-28）
gliflozin versus dapagliflozin added to metformin in pa‐ （编辑：孙 冰）

· 2290 · China Pharmacy 2025 Vol. 36 No. 18 中国药房 2025年第36卷第18期